HURN Stock Forecast & Price Target

Huron Consulting Gr is supported by durable demand for its healthcare-led consulting model, where clients facing higher operating costs, workforce constraints, and reimbursement pressure view its performance-improvement work as non-discretionary because it directly improves margins and cash flow. Its competitive edge is reinforced by deep proprietary benchmarking data, outcome-based contracts, strong executive sponsorship, and a service mix that includes about 5% of total revenue from fast-growing revenue cycle managed services and roughly 40% from digital services. Recent results and guidance add confidence, with Q1/26 RBR of $443.7 million up 12% year over year, healthcare revenue up 14%, adjusted EBITDA margin at 11.4%, and management reaffirming FY26 RBR growth of 7% to 12% alongside a path toward 2029 margin expansion.

Huron Consulting Gr is challenged by a deteriorating operating backdrop in healthcare and higher education, where structural pressures, tighter federal funding, and regulatory change may support demand but also constrain clients’ budgets and growth. Despite that demand, operating income margin was 8.2% versus 8.9% expected, while cash flow from operations worsened to ($162.2) million from ($106.8) million, reflecting higher compensation, software, and staffing costs. The valuation has already de-rated to 9.9x EV/NTM EBITDA from 14.3x at the beginning of 2026, and CY24’s expected revenue growth improvement may fail to materialize amid continued macro volatility.